Global analysis of the effects of the V2 receptor antagonist satavaptan on protein phosphorylation in collecting duct

American Journal of Physiology - Renal Physiology

Volumn 306, Issue 4, 2014, Pages

  Hoffert, Jason D ^a   Pisitkun, Trairak ^a,b   Saeed, Fahad ^a   Wilson, Justin L ^a   Knepper, Mark A ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Inner medullary collecting duct; ITRAQ; Mass spectrometry; Phos phoproteomics; Vasopressin

Indexed keywords

ALPHA ENDOSULFINE ISOFORM 2; AQUAPORIN 2; ARF GAP DOMAIN; BCL 2 RELATED OVARIAN KILLER PROTEIN; CALCIUM CALMODULIN DEPENDENT KINASE KINASE 2; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; CAMP DEPENDENT PROTEIN KINASE TYPE 1 ALPHA REGULATORY SUBUNIT; CARRIER PROTEINS AND BINDING PROTEINS; CATENIN BETA 1; CYCLIC AMP DEPENDENT PROTEIN KINASE; DESMOPRESSIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE SUBSTRATE 8 LIKE PROTEIN 1; FG REPEAT CONTAINING PROTEIN 1; KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY G MEMBER 2; KINESIN LIKE PROTEIN KIF13B; LEUCINE RICH REPEAT FLIGHTLESS INTERACTING PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; PEPTIDES AND PROTEINS; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN FAM83H; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SATAVAPTAN; UNCLASSIFIED DRUG; UREA TRANSPORTER UT A1; VESICLE TRAFFICKING PROTEIN SEC22B;

ACTIN FILAMENT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL JUNCTION; CONTROLLED STUDY; KIDNEY COLLECTING TUBULE; MALE; MICROTUBULE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION;

INNER MEDULLARY COLLECTING DUCT; ITRAQ; MASS SPECTROMETRY; PHOSPHOPROTEOMICS; VASOPRESSIN;

ANIMALS; KIDNEY TUBULES, COLLECTING; MORPHOLINES; PHOSPHOPEPTIDES; PHOSPHORYLATION; PROTEOME; PROTEOMICS; RATS; RECEPTORS, VASOPRESSIN; SIGNAL TRANSDUCTION; SPIRO COMPOUNDS;

EID: 84894079178     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00497.2013     Document Type: Article

References (49)

1. Aronson D, Verbalis JG, Mueller M, Krum H. Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study. Eur J Heart Fail 13: 327-336, 2011.
2. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, Pineyro G. Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci USA 100: 11406-11411, 2003.
3. Blount MA, Mistry AC, Frohlich O, Price SR, Chen G, Sands JM, Klein JD. Phosphorylation of UT-A1 urea transporter at serines 486 and 499 is important for vasopressin-regulated activity and membrane accumulation. Am J Physiol Renal Physiol 295: F295-F299, 2008.
4. Bockenhauer D, Carpentier E, Rochdi D, van'T HW, Breton B, Bernier V, Bouvier M, Bichet DG. Vasopressin type 2 receptor V88M mutation: molecular basis of partial and complete nephrogenic diabetes insipidus. Nephron Physiol 114: 1-10, 2010.
5. Bolger SJ, Hurtado PA, Hoffert JD, Saeed F, Pisitkun T, Knepper MA. Quantitative phosphoproteomics in nuclei of vasopressin-sensitive renal collecting duct cells. Am J Physiol Cell Physiol 303: C1006-C1020, 2012.
6. Chou CL, Christensen BM, Frische S, Vorum H, Desai RA, Hoffert JD, de LP, Nielsen S, Knepper MA. Non-muscle myosin II and myosin light chain kinase are downstream targets for vasopressin signaling in the renal collecting duct. J Biol Chem 279: 49026-49035, 2004.
7. Dayon L, Hainard A, Licker V, Turck N, Kuhn K, Hochstrasser DF, Burkhard PR, Sanchez JC. Relative quantification of proteins in human cerebrospinal fluids by MS/MS using 6-plex isobaric tags. Anal Chem 80: 2921-2931, 2008.
8. Douglass J, Gunaratne R, Bradford D, Saeed F, Hoffert JD, Steinbach PJ, Knepper MA, Pisitkun T. Identifying protein kinase target preferences using mass spectrometry. Am J Physiol Cell Physiol 303: C715-C727, 2012.
9. Elhassan EA, Schrier RW. The use of vasopressin receptor antagonists in hyponatremia. Expert Opin Investig Drugs 20: 373-380, 2011.
10. Elias JE, Gygi SP. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods 4: 207-214, 2007.
11. Frokiaer J, Marples D, Knepper MA, Nielsen S. Pathophysiology of aquaporin-2 in water balance disorders. Am J Med Sci 316: 291-299, 1998.
12. Gines P, Wong F, Watson H, Milutinovic S, Del Arbol LR, Olteanu D. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology 48: 204-213, 2008.
13. Grimsrud PA, Swaney DL, Wenger CD, Beauchene NA, Coon JJ. Phosphoproteomics for the masses. ACS Chem Biol 5: 105-119, 2010.
14. Hoffert JD, Fenton RA, Moeller HB, Simons B, Tchapyjnikov D, McDill BW, Yu MJ, Pistikun T, Chen F, Knepper MA. Vasopressin-stimulated increase in phosphorylation at ser-269 potentiates plasma membrane retention of aquaporin-2. J Biol Chem 283: 24617-24627, 2008.
15. Hoffert JD, Knepper MA. Taking aim at shotgun phosphoproteomics. Anal Biochem 375: 1-10, 2008.
16. Hoffert JD, Pisitkun T, Saeed F, Song JH, Chou CL, Knepper MA. Dynamics of the G protein-coupled vasopressin V2 receptor signaling network revealed by quantitative phosphoproteomics. Mol Cell Proteom-ics 11: M111, 2012.
17. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57, 2009.
18. Jean-Alphonse F, Perkovska S, Frantz MC, Durroux T, Mejean C, Morin D, Loison S, Bonnet D, Hibert M, Mouillac B, Mendre C. Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus. J Am Soc Nephrol 20: 2190-2203, 2009.
19. Jovanovich AJ, Berl T. Where vaptans do and do not fit in the treatment of hyponatremia. Kidney Int 83: 563-567, 2013.
20. Khositseth S, Pisitkun T, Slentz DH, Wang G, Hoffert JD, Knepper MA, Yu MJ. Quantitative protein and mRNA profiling shows selective post-transcriptional control of protein expression by vasopressin in kidney cells. Mol Cell Proteomics 10: M110, 2011.
21. Klussmann E, Tamma G, Lorenz D, Wiesner B, Maric K, Hofmann F, Aktories K, Valenti G, Rosenthal W. An inhibitory role of Rho in the vasopressin-mediated translocation of aquaporin-2 into cell membranes of renal principal cells. J Biol Chem 276: 20451-20457, 2001.
22. Kuwahara M, Fushimi K, Terada Y, Bai L, Marumo F, Sasaki S. cAMP-dependent phosphorylation stimulates water permeability of aqua-porin-collecting duct water channel protein expressed in Xenopus oocytes. J Biol Chem 270: 10384-10387, 1995.
23. Mertins P, Udeshi ND, Clauser KR, Mani DR, Patel J, Ong SE, Jaffe JD, Carr SA. iTRAQ labeling is superior to mTRAQ for quantitative global proteomics and phosphoproteomics. Mol Cell Proteomics 11: M111, 2012.
24. Miller ML, Jensen LJ, Diella F, Jorgensen C, Tinti M, Li L, Hsiung M, Parker SA, Bordeaux J, Sicheritz-Ponten T, Olhovsky M, Pas-culescu A, Alexander J, Knapp S, Blom N, Bork P, Li S, Cesareni G, Pawson T, Turk BE, Yaffe MB, Brunak S, Linding R. Linear motif atlas for phosphorylation-dependent signaling. Sci Signal 1: ra2, 2008.
25. Miller RL, Sandoval PC, Pisitkun T, Knepper MA, Hoffert JD. Vasopressin inhibits apoptosis in renal collecting duct cells. Am J Physiol Renal Physiol 304: F177-F188, 2013.
26. Morello JP, Salahpour A, Laperriere A, Bernier V, Arthus MF, Lonergan M, Petaja-Repo U, Angers S, Morin D, Bichet DG, Bouvier M. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest 105: 887-895, 2000.
27. Nedvetsky PI, Tabor V, Tamma G, Beulshausen S, Skroblin P, Kirschner A, Mutig K, Boltzen M, Petrucci O, Vossenkamper A, Wiesner B, Bachmann S, Rosenthal W, Klussmann E. Reciprocal regulation of aquaporin-2 abundance and degradation by protein kinase A and p38-MAP kinase. J Am Soc Nephrol 21: 1645-1656, 2010.
28. Noda Y, Horikawa S, Kanda E, Yamashita M, Meng H, Eto K, Li Y, Kuwahara M, Hirai K, Pack C, Kinjo M, Okabe S, Sasaki S. Reciprocal interaction with G-actin and tropomyosin is essential for aquaporin-2 trafficking. J Cell Biol 182: 587-601, 2008.
29. Pisitkun T, Bieniek J, Tchapyjnikov D, Wang G, Wu WW, Shen RF, Knepper MA. High-throughput identification of IMCD proteins using LC-MS/MS. Physiol Genomics 25: 263-276, 2006.
30. Pisitkun T, Jacob V, Schleicher SM, Chou CL, Yu MJ, Knepper MA. Akt and ERK1/2 pathways are components of the vasopressin signaling network in rat native IMCD. Am J Physiol Renal Physiol 295: F1030-F1043, 2008.
31. Rahmeh R, Damian M, Cottet M, Orcel H, Mendre C, Durroux T, Sharma KS, Durand G, Pucci B, Trinquet E, Zwier JM, Deupi X, Bron P, Baneres JL, Mouillac B, Granier S. Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy. Proc Natl Acad Sci USA 109: 6733-6738, 2012.
32. Ranadive SA, Ersoy B, Favre H, Cheung CC, Rosenthal SM, Miller WL, Vaisse C. Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus. Clin Endocrinol (Oxf) 71: 388-393, 2009.
33. Rinschen MM, Yu MJ, Wang G, Boja ES, Hoffert JD, Pisitkun T, Knepper MA. Quantitative phosphoproteomic analysis reveals vasopres-sin V2-receptor-dependent signaling pathways in renal collecting duct cells. Proc Natl Acad Sci USA 107: 3882-3887, 2010.
34. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels S, Purkayastha S, Juhasz P, Martin S, Bartlet-Jones M, He F, Jacobson A, Pappin DJ. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 3: 1154-1169, 2004.
35. Saeed F, Pisitkun T, Hoffert JD, Wang G, Gucek M, Knepper MA. An efficient dynamic programming algorithm for phosphorylation site assignment of large-scale mass spectrometry data. Proc IEEE Int Conf Bioin-formatics Biomed 618-625, 2012.
36. Saeed F, Pisitkun T, Knepper MA, Hoffert JD. Mining temporal patterns from iTRAQ mass spectrometry (LC-MS/MS) Data. Proc ISCA 3rd Int Conf Bioinformatics Comput Biol (BiCoB) 1: 152-159, 2011.
37. Sandoval PC, Slentz DH, Pisitkun T, Saeed F, Hoffert JD, Knepper MA. Proteome-wide measurement of protein half-lives and translation rates in vasopressin-sensitive collecting duct cells. J Am Soc Nephrol 24: 1793-1805, 2013.
38. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C, SALT Investigators. Tolvaptan, a selective oral vaso-pressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355: 2099-2112, 2006.
39. Serradeil-Le GC. An overview of SR121463, a selective non-peptide vasopressin V(2) receptor antagonist. Cardiovasc Drug Rev 19: 201-214, 2001.
40. Serradeil-Le GC, Lacour C, Valette G, Garcia G, Foulon L, Galindo G, Bankir L, Pouzet B, Guillon G, Barberis C, Chicot D, Jard S, Vilain P, Garcia C, Marty E, Raufaste D, Brossard G, Nisato D, Maffrand JP, Le FG. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest 98: 2729-2738, 1996.
41. Simon H, Gao Y, Franki N, Hays RM. Vasopressin depolymerizes apical F-actin in rat inner medullary collecting duct. Am J Physiol Cell Physiol 265: C757-C762, 1993.
42. Soupart A, Gross P, Legros JJ, Alfoldi S, Annane D, Heshmati HM, Decaux G. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol 1: 1154-1160, 2006.
43. Stokes JB, Grupp C, Kinne RK. Purification of rat papillary collecting duct cells: functional and metabolic assessment. Am J Physiol Renal Fluid Electrolyte Physiol 253: F251-F262, 1987.
44. Tamma G, Klussmann E, Maric K, Aktories K, Svelto M, Rosenthal W, Valenti G. Rho inhibits cAMP-induced translocation of aquaporin-2 into the apical membrane of renal cells. Am J Physiol Renal Physiol 281: F1092-F1101, 2001.
45. Tchapyjnikov D, Li Y, Pisitkun T, Hoffert JD, Yu MJ, Knepper MA. Proteomic profiling of nuclei from native renal inner medullary collecting duct cells using LC-MS/MS. Physiol Genomics 40: 167-183, 2010.
46. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367: 2407-2418, 2012.
47. Vossenkamper A, Nedvetsky PI, Wiesner B, Furkert J, Rosenthal W, Klussmann E. Microtubules are needed for the perinuclear positioning of aquaporin-2 after its endocytic retrieval in renal principal cells. Am J Physiol Cell Physiol 293: C1129-C1138, 2007.
48. Zhang Y, Wolf-Yadlin A, Ross PL, Pappin DJ, Rush J, Lauffenburger DA, White FM. Time-resolved mass spectrometry of tyrosine phosphor-ylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules. Mol Cell Proteomics 4: 1240-1250, 2005.
49. Zusman RM, Keiser HR. Prostaglandin E2 biosynthesis by rabbit re-nomedullary interstitial cells in tissue culture. Mechanism of stimulation by angiotensin II, bradykinin, and arginine vasopressin. J Biol Chem 252: 2069-2071, 1977.